Murine xenogeneic models of myelodysplastic syndrome: An essential roleforstroma cells

Experimental Hematology

Volumn 42, Issue 1, 2014, Pages 4-10

  Li, Xiang ^a   Deeg, H Joachim ^b,c  

^a JIANGNAN UNIVERSITY   (China)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD146 ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW; GENE OVEREXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; MESENCHYMAL STROMA CELL; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPLEEN; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD146; ANTIGENS, CD34; DISEASE MODELS, ANIMAL; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MYELODYSPLASTIC SYNDROMES; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84890034242     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.10.002     Document Type: Review

References (71)

1. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
2. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1538-1542.
3. Polednak A.P. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: Utility of multiple causes of death in surveillance. Cancer Epidemiol 2013, 37:569-574.
4. Intragumtornchai T., Prayoonwiwat W., Swasdikul D., et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998, 22:453-460.
5. Lee J.H., Lee J.H., Shin Y.R., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003, 17:305-313.
6. Greenberg P., Cox C., LeBeau M.M., et al. International scoring systemfor evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]. Blood 1997, 89:2079-2088.
7. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992, 6:52-59.
8. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985, 59:425-433.
9. Sanz G.F., Sanz M.A., Vallespì T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
10. Greenberg PL, Baer M, Bennett JM, etal. Myelodysplastic Syndromes. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 2004;v.1.2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf.
11. Greenberg P.L. Myelodysplastic syndromes: dissecting the heterogeneity. J Clin Oncol 2011, 29:1937-1938.
12. Helgason C.D., Damen J.E., Rosten P., et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998, 12:1610-1620.
13. Louz D., van den Broek M., Verbakel S., et al. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia 2000, 14:1876-1884.
14. Grisendi S., Bernardi R., Rossi M., et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005, 437:147-153.
15. Funk R.K., Maxwell T.J., Izumi M., et al. Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood 2008, 112:1434-1442.
16. Fenske T.S., McMahon C., Edwin D., et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res 2006, 66:5029-5038.
17. Kerbauy D.M.B., Lesnikov V., Torok-Storb B., Bryant E., Deeg H.J. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-b2microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells (Letter to the Editor). Blood 2004, 104:2202-2203.
18. Nilsson L., Åstrand-Grundström I., Anderson K., et al. Involvement and intrinsic deficiencies of hematopoietic stem cells in MDS patients with trisomy 8. Blood 2001, 98(Part 1):354a. #1491.
19. Li X., Marcondes A.M., Ragoczy T., Telling A., Deeg H.J. Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice. Blood Cancer J 2013, 3:e113.
20. Sanchez P.V., Perry R.L., Sarry J.E., et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009, 23:2109-2117.
21. Agliano A., Martin-Padura I., Mancuso P., et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008, 123:2222-2227.
22. Benito A.I., Bryant E., Loken M.R., et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003, 27:425-436.
23. Nilsson L., Astrand-Grundstrom I., Arvidsson I., et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96:2012-2021.
24. Thanopoulou E., Cashman J., Kakagianne T., Eaves A., Zoumbos N., Eaves C. Engraftment of NOD/SCID-b2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004, 103:4285-4293.
25. Takagi S., Saito Y., Hijikata A., et al. Membrane-bound human SCF/KL promotes invivo human hematopoietic engraftment and myeloid differentiation. Blood 2012, 119:2768-2777.
26. Tsujioka T., Matsuoka A., Tohyama Y., Tohyama K. Approach to new therapeutics: investigation by the use of MDS-derived cell lines. Curr Pharm Des 2012, 18:3204-3214.
27. Drexler H.G., Dirks W.G., Macleod R.A. Many are called MDS cell lines: one is chosen. Leuk Res 2009, 33:1011-1016.
28. Zhang J., Niu C., Ye L., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
29. Raaijmakers M.H.G.P., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2012, 464:852-857.
30. Raaijmakers M.H., Scadden D.T. Evolving concepts on the microenvironmental niche for hematopoietic stem cells (Review). Curr Opin Hematol 2008, 15:301-306.
31. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
32. Hale M.D., Hayden J.D., Grabsch H.I. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cellular Oncology 2013, 36:95-112.
33. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
34. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
35. Allen M., Jones J.L. Jekyll and Hyde: the role of the microenvironment on the progression of cancer (Review). J Pathol 2011, 223:162-176.
36. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
37. Jenkins M.K., Khoruts A., Ingulli E., et al. Invivo activation of antigen-specific CD4 T cells (Review). Annu Rev Immunol 2001, 19:23-45.
38. Mendez-Ferrer S., Michurina T.V., Ferraro F., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
39. Ferrer R.A., Wobus M., List C., et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 2013, 98:1677-1685.
40. Geyh S., Oz S., Cadeddu R.P., et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013, 27:1841-1851.
41. Roecklein B.A., Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995, 85:997-1005.
42. Bhagat T.D., Spaulding E., Sohal D., et al. MDS marrow stroma is characterized by epigenetic alterations. Blood 2008, 112:1243. #3635.
43. Mhyre A., Marcondes A.M., Spaulding E.Y., Deeg H.J. Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD. Blood 2009, 113:649-658.
44. Li X., Marcondes A.M., Gooley T.A., Deeg H.J. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 2010, 116:2304-2314.
45. Kerbauy D.M.B., Mhyre A., Bryant E., Deeg H.J. Do MDS-derived clonal hematopoietic precursors require human stroma support for survival. Curr Res Hematol 2007, 1:1-13.
46. Muguruma Y., Matsushita H., Yahata T., et al. Establishment of a xenograft model of human myelodysplastic syndromes. Haematologica 2011, 96:543-551.
47. Graf L., Iwata M., Torok-Storb B. Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a. Blood 2002, 100:1509-1511.
48. Tormin A., Li O., Brune J.C., et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood 2011, 117:5067-5077.
49. Pillai M.M., Yang X., Balakrishnan I., Bemis L., Torok-Storb B. MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells. PLoS ONE 2010, 5:e14304.
50. Sacchetti B., Funari A., Michienzi S., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
51. Wang Z., Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013, 330:150-162.
52. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., Meyertholen K.E., O'Connor K.C. Invitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798.
53. Corselli M., Chin C.J., Parekh C., et al. Perivascular support of human hematopoietic stem/progenitor cells. Blood 2013, 121:2891-2901.
54. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
55. Pinnix C.C., Lee J.T., Liu Z.J., et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009, 69:5312-5320.
56. Levesque J.P. A niche in a dish: pericytes support HSC. Blood 2013, 121:2816-2818.
57. Montemurro T., Andriolo G., Montelatici E., et al. Differentiation and migration properties of human foetal umbilical cord perivascular cells: potential for lung repair. J Cell Mol Med 2011, 15:796-808.
58. Duda D.G., Duyverman A.M., Kohno M., et al. Malignant cells facilitate lung metastasis by bringing their own soil. PNAS 2010, 107:21677-21682.
59. Deeg H.J. Marrow stroma in MDS: culprit or bystander?. Leuk Res 2002, 26:687-688.
60. Soenen V., Kotb R., Bonnet M.L., et al. Mesenchymal cells (MC) generated from patients with myelodysplastic syndromes (MDS) are devoid of cytogenetic abnormalities and support short and long-term hematopoiesis. Blood 2001, 98(Part 1):729a. #3041.
61. Elstner E., Wachter M., Ihle R. Bone marrow stromal culture from patients with myelodysplastic syndromes and patients at different stages of acute nonlymphocytic leukaemia. Folia Haematologica Int Mag Klin Morphol Blutforsch 1989, 116:167-174.
62. Weimar I.S., Voermans C., Bourhis J.H., et al. Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia 1998, 12:1195-1203.
63. Aizawa S., Nakano M., Iwase O., et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation invitro. Leuk Res 1999, 23:239-246.
64. Mangi M.H., Newland A.C. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther 1999, 5:87-95.
65. Tormo M., Marugan I., Calabuig M. Myelodysplastic syndromes: an update on molecular pathology. Clin Transl Oncol 2010, 12:652-661.
66. Manakova T.E., Tsvetaeva N.V., Levina A.A., et al. Invivo production of cytokines by bone marrow stromal cells and macrophages from patients with myelodysplastic syndrome. Bull Exp Biol Med 2001, 132:633-636.
67. Lubkova O.N., Tzvetaeva N.V., Momotyuk K.S., Belkin V.M., Manakova T.E. VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes. Bull Exp Biol Med 2011, 151:13-15.
68. Crump M.P., Gong J.H., Loetscher P., et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997, 16:6996-7007.
69. Askari A.T., Unzek S., Popovic Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
70. Segers V.F., Tokunou T., Higgins L.J., MacGillivray C., Gannon J., Lee R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692.
71. Franz W.M., Zaruba M., Theiss H., David R. Stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:675-676.